Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in both the airways causing airway obstruction and the lung tissues causing emphysema. The disease is induced by inhalation of noxious gasses and particulate matter resulting in a chronic persistent inflammatory response in the lung, and the extent of the inflammatory reaction correlates with the severity of the disease. This chronic inflammatory response in the lung is also associated with a significant systemic inflammatory response with downstream adverse clinical health effects. The systemic response in COPD is associated with mortality, specifically cardiovascular mortality. This review describes the nature of the systemic inflammatory response in COPD and the clinical manifestations associated with the systemic response, with a focus on the potential mechanisms for these adverse health effects.

Keywords:
Chronic obstructive pulmonary disease, Cytokines, Inflammation, systemic, Proteins, phase reactive, Bone marrow
1.
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256–1276.
2.
Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245–1257.
3.
Hogg JC: Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709–721.
4.
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645–2653.
5.
Hogg JC, Senior RM: Chronic obstructive pulmonary disease. Part 2. Pathology and biochemistry of emphysema. Thorax 2002;57:830–834.
6.
Jeffery PK: Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998;53:129–136.
7.
Chanez P, Vignola AM, O’Shaugnessy T, et al: Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529–1534.
8.
Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, et al: CD8+ cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711–717.
9.
Saetta M, Turato G, Facchini FM, Corbino L, Lucchini RE, Casoni G, Maestrelli P, Mapp CE, Ciaccia A, Fabbri LM: Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997;156:1633–1639.
10.
Baraldo S, Turato G, Badin C, Bazzan E, Beghe B, Zuin R, Calabrese F, Casoni G, Maestrelli P, Papi A, et al: Neutrophilic infiltration within the airway smooth muscle in patients with COPD. Thorax 2004;59:308–312.
11.
Oudijk EJ, Lammers JW, Koenderman L: Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:5s–13s.
12.
Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530–534.
13.
Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF: Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers: regulation by interleukin-10. Am J Respir Crit Care Med 2000;162:1355–1360.
14.
Morrison D, Strieter RM, Donnelly SC, Burdick MD, Kunkel SL, MacNee W: Neutrophil chemokines in bronchoalveolar lavage fluid and leukocyte-conditioned medium from nonsmokers and smokers. Eur Respir J 1998;12:1067–1072.
15.
Kuschner WG, D’Alessandro A, Wong H, Blanc PD: Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 1996;9:1989–1994.
16.
MacNee W, Rahman I: Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001;7:55–62.
17.
Masubuchi T, Koyama S, Sato E, et al: Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Pathol 1998;153:1903–1912.
18.
Nishikawa M, Kakemizu N, Ito T, et al: Superoxide mediates cigarette smoke-induced infiltration of neutrophils into the airways through nuclear factor-κB activation and IL-8 mRNA expression in guinea pigs in vivo. Am J Respir Cell Mol Biol 1999;20:189–198.
19.
Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL: Tumor necrosis factor-α drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004;170:492–498.
20.
Takanashi S, Hasegawa Y, Kanehira Y, Yamamoto K, Fujimoto K, Satoh K, Okamura K: Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999;14:309–314.
21.
de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS, van Krieken JH: Transforming growth factor-β1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1951–1957.
22.
Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y, Yamasawa F, Nakahara K, Umeda A: Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001;163:1476–1483.
23.
Hogg JC: Why does airway inflammation persist after the smoking stops? Thorax 2006;61:96–97.
24.
Torres JL, Ridker PM: Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol 2003;18:471–478.
25.
Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514–1519.
26.
Shaaban R, Kony S, Driss F, Leynaert B, Soussan D, Pin I, Neukirch F, Zureik M: Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. Respir Med 2007;100:2112–2120.
27.
Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61:23–28.
28.
Sin DD, Lacy P, York E, et al: Effects of fluticasone on systematic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760–765.
29.
Malo O, Sauleda J, Busquets X, et al: Systemic inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2002;38:172–176.
30.
Jousilahti P, Salomaa V, Rasi V, Vahtera E: Symptoms of chronic bronchitis, haemostatic factors, and coronary heart disease risk. Atherosclerosis 1999;142:403–407.
31.
Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW: Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210–215.
32.
Fowkes FG, Anandan CL, Lee AJ, Smith FB, Tzoulaki I, Rumley A, Powell JT, Lowe GD: Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease. J Vasc Surg 2006;43:474–480.
33.
Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006;174:867–874.
34.
Joppa P, Petrasova D, Stancak B, Tkacova R: Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006;130:326–333.
35.
Friedman GD, Arthur MS, Siegelaub AB: The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974;290:1275–1278.
36.
Grimm RH, Neaton JD, Ludwig W: Prognostic importance of the white cell count for coronary, cancer and all cause mortality. JAMA 1985;254:1932–1937.
37.
Weiss ST, Segal MR: Relationship of FEV1 and peripheral blood leukocyte counts to total mortality. Am J Epidemiol 1995;142:493–498.
38.
Corre F, Lellouch J, Schwartz D: Smoking and leukocyte counts: results of an epidemiological survey. Lancet 1971;ii:632–634.
39.
Chan-Yeung M, Abboud R, Buncio AD, Vedal S: Peripheral leukocyte count and longitudinal decline in lung function. Thorax 1988;43:462–466.
40.
van Eeden SF, Hogg JC: Changes in peripheral blood polymorphonuclear leukocytes indicative of bone marrow stimulation in chronic smokers. Eur Respir J 2000;15:915–921.
41.
Terashima T, Wiggs B, English D, Hogg JC, Van Eeden SF: The effect of cigarette smoking on the bone marrow. Am J Respir Crit Care Med 1997;155:1021–1026.
42.
Bicknell S, van Eeden SF, Hayashi S, Hards J, English J, Hogg JC: A non-radioisotopic method for tracing neutrophils in vivo using 5′-bromo-2′-deoxyuridine. Am J Respir Cell Mol Biol 1994;10:16–23.
43.
Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF: Polymorphonuclear leukocyte transit times in bone marrow during streptococcal pneumonia. Am J Physiol 1996;271:L587–L592.
44.
Terashima T, Klut ME, English D, Hards J, Hogg JC, van Eeden SF: Chronic cigarette smoking causes sequestration of polymorphonuclear leukocytes released from the bone marrow in pulmonary capillaries. Am J Respir Cell Mol Biol 1998;20;171–177.
45.
Goto Y, Hogg JC, Suwa T, Quinlan KB, van Eeden SF: A novel method to quantify the turnover and release of monocytes from the bone marrow using the thymidine analog, 5′-bromo-2′-deoxyuridine. Am J Physiol Cell Physiol 2003;285:C253–C259.
46.
Goto Y, Hogg JC, Whalen B, Shih C-H, Ishii H, van Eeden SF: Monocyte recruitment into the lungs in pneumococcal pneumonia. Am J Respir Cell Mol Biol 2004;30:620–626.
47.
Goto Y, Hogg JC, Shih CH, Ishii H, Vincent R, van Eeden SF: Exposure to ambient particles accelerates monocyte release from the bone marrow in atherosclerotic rabbits. Am J Physiol Lung Cell Mol Physiol 2004;287:L79–L85.
48.
Shapiro SD: The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S29–S32.
49.
Jiang Y, Beller DI, Frendl G, Graves DT: Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992;148:2423–2428.
50.
Chung KF: Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001;18:50s–59s.
51.
Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ: Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1414–1418.
52.
Di Francia M, Barbier D, Mege JL, Orehek J: Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453–1455.
53.
Gustafsson A, Asman B, Bergstrom K: Cigarette smoking as an aggravating factor in inflammatory tissue-destructive diseases: increase in tumor necrosis factor-α priming of peripheral neutrophils measured as generation of oxygen radicals. Int J Clin Lab Res 2000;30:187–190.
54.
Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, MacNee W, Agusti AG: Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001;56:432–437.
55.
de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM: Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996;153:633–637.
56.
Schols AM, Buurman WA, Staal-van den Brekel AJ, Dentener MA, Wouters EFM: Evidence for the relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with COPD. Thorax 1996;51:819–824.
57.
Dentener MA, Creutzberg EC, Schols AM, Mantovani A, van’t Veer C, Buurman WA, Wouters EF: Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001;56:721–726.
58.
Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X: Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347–360.
59.
van Eeden SF, Yeung A, Quinlam K, Hogg JC: Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:61–67.
60.
Terashima T, English D, Hogg JC, van Eeden SF: The release of polymorphonuclear leukocyte from the bone marrow by interleukin 8. Blood 1998;92:1062–1069.
61.
Mukae H, Zamfir D, English D, Hogg JC, van Eeden SF: Polymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor: intravascular behavior. Hemat J 2000;1:159–171.
62.
Suwa T, Hogg JC, Englis D, van Eeden SF: Interleukin-6 induced neutrophilia: contribution of bone marrow release and demargination of intravascular neutrophils. Am J Physiol 2000;279:H2954–H2960.
63.
Jansen JH, Kluin-Nelemans JC, van Damme J, Wientjens GJ, Willemze R, Fibbe WE: Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells. J Exp Med 1992;175:1151–1154.
64.
Suwa T, Hogg JC, Klut ME, Hards J, van Eeden SF: Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. Am J Respir Crit Care Med 2001;163:970–976.
65.
Van Eeden SF, Kitagawa Y, Sat Y, Hogg JC: Polymorphonuclear leukocytes released from the bone marrow and acute lung injury. Chest 1999;116:S43–S46.
66.
Mire-Sluis A, Thorpe R (eds): Cytokines. San Diego, Academic Press, 1999, pp 1–547.
67.
Topham MK, Carveth HJ, McIntyre TM, Prescott SM, Zimmerman GA: Human endothelial cells regulate polymorphonuclear leukocyte degranulation. FASEB J 1998;12:733–746.
68.
Ridker PM: Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999;130:933–937.
69.
Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417–424.
70.
Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G: Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995;73:374–379.
71.
Mukae H, Vincent R, Quinlan K, English D, Hards J, Hogg JC, van Eeden SF: The effect of repeated exposure to particulate air pollution (PM10) on the bone marrow. Am J Respir Crit Care Med 2001;163:201–209.
72.
Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF: Phagocytosis of small carbon particles by alveolar macrophages stimulates the release of PMN from the bone marrow. Am J Respir Crit Care Med 1997;155:1441–1447.
73.
Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, Rennard SI: Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 1997;155:1770–1776.
74.
Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, van Eeden SF: Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002;39:935–942.
75.
Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255–1262.
76.
Sin DD, Wu L, Man SF: The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952–1959.
77.
Beaty TH, Newill CA, Cohen BH, Tockman MS, Bryant SH, Spurgeon HA: Effects of pulmonary function on mortality. J Chronic Dis 1985;38:703–710.
78.
Stein PD, Beemath A, Meyers FA, Olson RE: Pulmonary embolism and deep venous thrombosis in hospitalized adults with chronic obstructive pulmonary disease. J Cardiovasc Med (Hagerstown) 2007;8:253–257.
79.
Speizer FE, Fay ME, Dockery DW, Ferris BG Jr: Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis 1989;140:S49–S55.
80.
Schunemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M: Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118:656–664.
81.
Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM: Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br Med J 1996;313:711–715.
82.
Janssens JP, Herrmann F, MacGee W, Michel JP: Cause of death in older patients with anatomo-pathological evidence of chronic bronchitis or emphysema: a case-control study based on autopsy findings. Am Geriatr Soc 2001;49:571–576.
83.
Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O’Hara P, et al: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497–1505.
84.
Wise RA, McGarvey LP, John M, Anderson JA, Zvarich MT: Reliability of cause-specific mortality adjudication in COPD clinical trial. Proc Am Thorac Soc 2006;3:A120.
85.
Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
86.
Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000;321:199–204.
87.
Lusis AJ: Atherosclerosis. Nature 2000;407:233–241.
88.
Yeh ET, Anderson HV, Pasceri V, Willerson JT: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001;104:974–975.
89.
Van Doornum S, McColl G, Wicks IP: Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862–873.
90.
Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173–1177.
91.
Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399–2406.
92.
Sin DD, Man SF: Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol 2005;83:8–13.
93.
Morley JE, Thomas DR, Wilson MM: Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735–743.
94.
Schols AMWJ: Nutrition in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000;6:110–115.
95.
Vandenbergh E, Van de Woestijne KP, Gyselen A: Weight changes in the terminal stages of chronic obstructive pulmonary disease. Am Rev Respir Dis 1967;95:556–566.
96.
Creutzberg EC, Schols AM, Bothmer-Quaedvlieg FCM, Wouters EFM: Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr 1998;52:396–401.
97.
Agusti AGN: Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:367–370.
98.
Hallin R, Koivisto-Hursti U-K, Lindberg E, Janson C: Nutritional status, dietary energy intake and the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD). J Respir Med 2006;100:561–567.
99.
Schols AM, Slangen J, Volovics L, Wouters EF: Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791–1797.
100.
Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP: Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856–1861.
101.
Sin DD, Jones RL, Mannino DM, Paul Man SF: Forced expiratory volume in 1 second and physical activity in the general population. Am J Med 2004;117:270–273.
102.
Montes de Oca M, Rassulo J, Celli BR: Respiratory muscle and cardiopulmonary function during exercise in very severe COPD. Am J Respir Crit Care Med 1996;154:1284–1289.
103.
Wing SS, Goldberg AL: Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 1993;264:E668–E676.
104.
Laghi F: Low testosterone in chronic obstructive pulmonary disease: does it really matter? Am J Respir Crit Care Med 2005;172:1069–1070.
105.
Langen RC, Schols AM, Kelders MC, van der Velden JL, Wouters EF, Janssen-Heininger YM: Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol, 2006;35:689–696.
106.
Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr: NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000;289:2363–2366.
107.
Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004;114:370–378.
108.
Mador MJ, Bozkanat E: Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res 2001;2:216–224.
109.
Agusti AGN, Sauleda J, Miralles C, et al: Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:485–489.
110.
Agusti AGN, Morla M, Sauleda J, et al: NF-κB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004;59:483–487.
111.
Casaburi R: Skeletal muscle function in COPD. Chest 2000;117(suppl 1):267S–271S.
112.
Sin DD, Man JP, Man SF: The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003;114:10–14.
113.
de Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW: Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005;25:879–884.
114.
Lee TA, Weiss KB: Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:855–859.
115.
Suissa S, Baltzan M, Kremer R, Ernst P: Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004;169:83–88.
116.
Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ: Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:1286–1293.
117.
Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S, Patane F, Agliano AM, Spera G, Marigliano V, Ammendola S, Agnusdei D, Migliaccio S, Scandurra R: Raloxifene modulates interleukin-6 and tumor necrosis factor-α synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 2004;89:6097–6099.
118.
Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1–7.
119.
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304–309.
120.
Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski RM, Singh B, Ellen RP, Penninger JM: Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106:R59–R67.
121.
Biskobing DM: COPD and osteoporosis. Chest 2002;121:609–620.
122.
Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA, Speizer FE, Barr RG, Camargo CA Jr: Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004;27:2478–2484.
123.
Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384–2389.
124.
Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649–1652.
125.
Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286–1292.
126.
Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG: Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999;84:272–278.
127.
Sonnenberg GE, Krakower GR, Kissebah AH: A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180–186.
128.
Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296–1301.
129.
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930–1935.
130.
Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H: The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003;27:443–449.
131.
Sidhu JS, Cowan D, Kaski JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003;42:1757–1763.
132.
Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P: Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306–1312.
133.
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679–684.
134.
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–1012.
135.
Antonelli-Incalzi R, Imperiale C, Bellia V, et al: Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003;22:444–449.
136.
Domingo-Salvany A, Lamarca R, Ferrer M, et al: Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:680–685.
137.
Engstrom G, Hedblad B, Janzon L, Valind S: Respiratory decline in smokers and ex-smokers – an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk 2000;7:267–272.
138.
Tockman MS, Pearson JD, Fleg JL, Metter EJ, Kao SY, Rampal KG, Cruise LJ, Fozard JL. Rapid decline in FEV1: a new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med 1995;151:390–398.
139.
Groenewegen KH, Dentener MA, Wouters EF: Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. Respir Med 2007;101:2409–2415.
140.
Engström G, Wollmer P, Hedblad B, Juul-Möller S, Valind S, Janzon L: Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from ‘men born in 1914’, Malmö, Sweden. Circulation 2001;103:3086–3091.
141.
Higgins MW, Keller JB: Predictors of mortality in the adult population of Tecumseh. Arch Environ Health 1970;21:418–424.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.